Bristol Myers Squibb partnered with Anthropic to deploy Claude AI across its global operations, targeting enterprise-wide acceleration in drug discovery and development. BMS said it will integrate Claude across research, clinical development, manufacturing, commercial operations, and corporate functions, positioning the platform as a shared “intelligence system” for more than 30,000 employees. BMS outlined near-term priorities that go beyond chat interfaces, including using Claude Code for engineering acceleration and evaluating Claude as an agentic layer in workflows that support trial documentation and regulatory submission tasks. The company framed the approach as unlocking value held in scientific, molecular, and clinical data silos. The deal reflects how large pharma are shifting AI deployments toward workflow automation and data synthesis that can interact with operational processes rather than producing standalone answers.